A | B | C | |
---|---|---|---|
1 | Main | ||
2 | Brand | fka SAGE-217 | |
3 | Generic | zuranolone | |
4 | MOA | GABA-A pam, synaptic and extrasynaptic receptors (handwaving?) | |
5 | Clinical Trials | ||
6 | Phase III CORAL | ||
7 | -8.9 zur+ADT vs. 7.0 placebo+ADT at day 3 | ||
8 | 11.7 zur vs. -10.1 at day 15? | ||
9 | Day 42, no better than ADT | ||
10 | |||
11 | Phase III WATERFALL | ||
12 | |||
13 | |||
14 | |||
15 | Phase III "SHORELINE" | ||
16 | |||
17 | |||
18 | Phase III "MOUNTAIN" - NCT03672175 outpatient vs placebo. 30mg, 20mg, placebo | ||
19 | Day 15 HDRS-17 failed to meet PE, p=0.116 | ||
20 | -12.5 vs. -11.1 for placebo, -11.5 for 20mg. |